Cas-CLOVER: The Clean Alternative to CRISPR with IP Freedom

The only CRISPR alternative built for bioprocessing: de-risked, simple licensing that accelerates timelines across your entire pipeline.

Request Licensing Info

Our BPI 2025 Webcast Now On Demand. Watch the full recorded session and Q&A. Click Here!

Seamless know-how transfer across biologics R&D and manufacturing. Evaluate Cas-CLOVER or CleanCut CHO, then license with confidence.

Licensing Journey

Technology Transfer

Evaluate

Assess its potential

License

Execute an agreement

Evaluate confidently with expert support and rigorously validated methods.
Put the technology to the test with our technical support

Gene Editing: The Cas-Clover Advantage

Cas-CLOVER Other Tools
IP CLARITY
 Encumbered IP
High precision
 Off-targets
Discovery to production
 Limited scale
BioPharma, CDMO
 Narrow use
Streamlined
 Complex

Why Partner With Demeetra

We help biotech innovators accelerate discovery and scale production with technologies built for precision, efficiency, and freedom to operate

Freedom to Operate (FTO)

No entangling IP restrictions

Dual-use Technology

From research to production with the same cells & tools

Expert Support

Partnering with scientists and BD teams every step of the way

Proven Performance

Cas-CLOVER and CleanCut CHO already powering leading programs
Demeetra's Technology Suite Banner

Cas-CLOVER

Cas-CLOVER ‘the clean alternative to CRISPR/Cas9’ introduces targeted double-strand breaks in genomic DNA, enabling knockouts and site directed knock-ins with high precision.
Learn More

CleanCut GS CHO

Engineered with Cas-CLOVER technology, CleanCut GS CHO delivers competitive titers and industry-leading productivity. Demeetra’s CleanCut GS CHO cells demonstrate exceptional viability and recovery times, with doubling times of less than 20 hours.

Learn More

Harbor-IN Transposase

License-Free transposase for high productivity biologics production. Say goodbye to transposase licensing roadblocks! Harbor-IN integrates at stable and highly expressed genomic regions, optimized for robust and sustained bioproduction.

Learn More

Trusted By Leading Biotechnology Organizations

Elanco Logo
Poseida Therapeutics logo
Sanofi logo
AGC Biologics logo
Indiana University logo
IITA Transforming African Agriculture logo
VBI Vaccines logo

As Seen In Top Tier Publications

Our gene editing technology has been featured in leading publications.

Plant Biotechnology Journal logo
Molecular Therapy Nucleic Acids logo
Journal of Fungi logo
Fermentation Banner

Proven in Practice

Leading scientists are utilizing Cas-CLOVER to achieve precise and efficient results in real-world research.

“

Cas-CLOVER enhanced our CHO line protein expression with no observable off-target mutations.

Dr. Kayla Bean

Elanco

“

Cas-CLOVER enabled >90% STAT1 knockout in HEK293 cells used for rAAV production.

Takeda Pharmaceuticals, Inc.

Andorfer et al. 2024 Biotechnol. J.

“

Cas-CLOVER demonstrates significantly lower off-target activity…with a fidelity possibly up to 25-fold greater than CRISPR-Cas9.

Poseida Therapeutics, Inc.

Madison et al. 2022 Molecular Therapy Nucleic Acids.

We provide commercial gene editing licenses backed by leading gene-editing experts.

Contact us to learn more about our independent gene editing technology IP, optimized reagents and internal expertise to help guide smooth adoption.